Engaging Investors in A Complex Science Enterprise

bit.bio, a leading synthetic biology enterprise, was seeking to raise its profile with investors, policymakers, and the scientific community by refining its messaging and communications. It wanted to position members of its staff as thought leaders in the sector and demonstrate the breadth and depth of talent it packs in its ranks.

bit.bio needed to secure funding for the next phase of its growth plans. To do so, it needed to create confident messaging that would cut through the competition’s and convince prospective investors of the inherent value and financial potential of its work.

To raise bit.bio’s profile and investor confidence, we developed video content to attract and engage key stakeholders across pharma, science, and business. This was done alongside successful pitches of thought leadership articles and interviews with numerous tier 1 media outlets.

We also secured tens of high-value meetings for bit.bio with industry and governmental leaders, including an event, networking reception, and dinner in Parliament in partnership with the Parliamentary and Scientific Committee.

Thanks to coverage in Forbes, The Times, Money Week, BBC News, Wired, and the European Pharmaceutical Review to scheduled meetings with Minister for Science, George Freeman MP and Minister for the Cabinet Office, Steve Barclay MP, we were able to drive significant investment in bit.bio’s Series B round of funding.